KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Research & Development (2016 - 2025)

Historic Research & Development for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $372.2 million.

  • Alnylam Pharmaceuticals' Research & Development rose 2400.28% to $372.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 1718.5%. This contributed to the annual value of $1.3 billion for FY2025, which is 1718.5% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Research & Development of $372.2 million as of Q4 2025, which was up 2400.28% from $358.8 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Research & Development high stood at $372.2 million for Q4 2025, and its period low was $169.9 million during Q1 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Research & Development value was $257.1 million (recorded in 2023), while the average stood at $256.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 3595.97% in 2021, then crashed by 861.01% in 2022.
  • Alnylam Pharmaceuticals' Research & Development (Quarter) stood at $229.0 million in 2021, then grew by 14.4% to $262.0 million in 2022, then increased by 3.86% to $272.1 million in 2023, then increased by 10.3% to $300.2 million in 2024, then grew by 24.0% to $372.2 million in 2025.
  • Its last three reported values are $372.2 million in Q4 2025, $358.8 million for Q3 2025, and $323.6 million during Q2 2025.